天港医诺：预计每年有1个至2个产品进入临床研究阶段

Core Insights - Two innovative immunotherapy drugs targeting NK cell pathways have recently entered Phase I clinical trials at Peking University Cancer Hospital and Fudan University Shanghai Cancer Center, marking a significant milestone for the company [1][2] - The bispecific antibody drug is the first of its kind in clinical stages in China, with no similar drugs approved globally, showing potential for treating colorectal cancer and other target-positive solid tumors [1] - The monoclonal antibody drug covers multiple indications, including liver cancer and melanoma, providing new treatment options for patients [1] Company Developments - The entry of these two drugs into the clinical trial phase is a crucial milestone for the company, which aims to advance more "China-made" innovative therapies from the lab to clinical settings [2] - The company plans to continue developing its clinical pipeline, with an expectation of 1 to 2 products entering clinical research each year, and is actively pursuing overseas licensing agreements [2] - The company has established close relationships with several multinational pharmaceutical companies to facilitate project development [2]